/

SNGX

Soligenix, Inc.Closed

0.3348−0.02 −4.81%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

0.3500

Prev close

0.3517

Day range

0.33130.3670

52-week range

0.28001.76

Volume

267.34K1.11×

Mkt cap

7.29M

P/E ttm

—

Fwd P/E

-1.34

EPS ttm

-0.7900

Div yield

0.00%

Earnings

—

From 52w high

−80.98%

Price Chart

Yahoo Finance · delayed

SNGXOct 13, 2026O 0.3500H 0.3700L 0.3300C 0.3300−0.0200 (−5.71%)Vol 267.40K

SMA 500.3756
SMA 2000.7482

1Y change −80.81% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SNGX Soligenix, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −8.33%
1 month: −8.33%
3 months: −10.81%
6 months: −71.30%
Year to date: −75.37%
1 year: −80.81%

Valuation & ownership

Market cap: 7.29M
Enterprise value: −2.22M
P/E (ttm): —
Forward P/E: -1.34
PEG ratio: —
Price / book: 1.09
Price / sales (ttm): —
EV / EBITDA: 0.20
EPS (ttm): -0.7900
EPS (forward): -0.2500
Beta (5y monthly): 2.00
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 21.77M
Float: 21.66M
Short % of float: 0.77%
Short ratio (days): 0.71
Held by insiders: 4.59%
Held by institutions: 6.72%
Avg volume (3m): 240.83K
50-day average: 0.3766
200-day average: 0.7538
52-week change: −80.81%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 31.9
vs 50-day SMA: −12.14%
vs 200-day SMA: −55.89%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.59%
Realised vol (20d, ann.): 45.4%
From 52-week high: −81.25%
From 52-week low: +17.86%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

1.38

+310.69% implied

Low 1.25Median 1.38High 1.50

Recommendation trend

Now1 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →

DES

About Soligenix, Inc.

Yahoo Finance profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Sector: Healthcare
Industry: Biotechnology
Employees: 13
Headquarters: Princeton, NJ, United States
Website: soligenix.com
Officers

SEAS

Seasonality · SNGX

2007–2026 · monthly returns

Strongest month Jan +27.47%Weakest month May −9.93%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-6.7	-5.6	0.0	-70.3	160.0	-56.0	-7.5	2.7	-5.3	-7.0			−75.0%
2025	-13.7	-0.9	-6.9	-8.4	-4.1	-30.7	123.7	5.8	-62.6	33.6	2.6	-15.7	−50.4%
2024	-11.8	9.0	-17.8	-35.0	-17.9	-49.6	63.2	-16.9	13.4	-7.6	-8.7	-19.4	−77.8%
2023	-2.2	-54.1	-35.0	-21.8	-53.2	-2.8	-10.0	-28.6	24.4	-14.3	104.2	-22.4	−88.7%
2022	-6.1	16.1	1.4	-27.4	9.4	3.4	46.7	-11.4	-43.6	54.5	-17.6	-19.6	−31.8%
2021	21.1	6.5	-7.3	-5.9	-29.2	8.8	-14.4	10.5	1.0	-4.7	-12.9	-25.0	−48.4%
2020	88.3	10.6	-44.4	-7.7	23.2	10.5	5.2	-11.3	-9.1	-5.0	33.5	-43.6	−11.7%
2019	4.7	8.9	-6.1	-20.7	-4.1	1.4	81.7	-22.5	-5.0	-5.3	11.1	45.0	+68.6%
2018	-0.9	-8.6	-3.0	-15.4	-7.9	-36.2	26.8	29.3	18.2	-39.4	-2.6	-22.5	−61.3%
2017	12.0	-21.4	36.4	14.1	-20.8	-16.0	14.6	-9.8	5.2	-9.9	1.0	9.4	−1.3%
2016	-22.1	0.0	-4.5	-8.3	-5.2	-9.6	-4.5	1.6	20.3	-41.6	-10.9	-43.9	−80.1%
2015	17.3	40.9	4.3	0.6	-5.9	46.9	-30.6	-12.3	-25.2	-8.4	-1.0	16.5	+15.3%
2014	23.9	-4.9	5.7	-10.3	-9.5	17.0	-6.1	1.0	-1.0	-3.0	-24.2	-33.3	−45.6%
2013	198.3	-2.8	-15.5	-4.8	4.3	-27.4	55.7	9.1	16.1	-2.9	-2.0	-9.5	+200.0%
2012	33.3	-22.5	-27.4	-26.7	-15.2	0.0	35.7	5.3	32.5	-17.0	52.3	-10.4	0.0%
2011	-5.3	0.0	5.6	15.8	-9.1	25.0	20.0	-6.7	-85.7	0.0	-25.0	0.0	−84.2%
2010	-4.0	8.3	3.8	3.7	-3.6	-7.4	0.0	-8.0	-21.7	0.0	-11.1	18.8	−24.0%
2009	66.7	30.0	-15.4	0.0	18.2	38.5	16.7	-4.8	40.0	-28.6	5.0	19.0	+316.7%
2008	5.9	27.8	-26.1	-11.8	6.7	-25.0	8.3	-23.1	0.0	-30.0	28.6	-33.3	−64.7%
2007	116.7	3.8	-3.7	53.8	-65.0	17.9	-12.1	13.8	12.1	-45.9	-20.0	6.3	−29.2%

INSD

Insider Activity · SNGX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Oct 1, 2025	Schaber Christopher JChief Executive Officer	Purchase at price 1.32 per share.	15.1K	$20.00K

SNGX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SNGX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Soligenix, Inc.

Seasonality · SNGX

Insider Activity · SNGX

Congress Trades · SNGX

Investors Holding SNGX

Investors Holding SNGX

Congress Trades · SNGX

Insider Activity · SNGX

Seasonality · SNGX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Soligenix, Inc.

Earnings & Dividends

News